$Moleculin Biotech(MBRX.US)$Reuters· 1 min ago Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data
$Moleculin Biotech(MBRX.US)$ NEWS European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
$Moleculin Biotech(MBRX.US)$Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML 2 MINUTES AGO, 9:05 AM EDT VIA PR NEWSWIRE
Breakthrough in AML Treatment: Moleculin's Annamycin Shows Promising Results. Acute Myeloid Leukemia (AML) remains one of the most challenging blood cancers to treat, with survival rates that have seen only modest improvements over the past decades. However, a beacon of hope shines from recent developments in clinical trials conducted by Moleculin Biotech, Inc., showcasing significant progress in the battle against this devastat...
$Moleculin Biotech(MBRX.US)$Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects AnnAraC has potential to fill significant unmet need and expected to increase 2nd line AML CRs more than double over existing 2nd line therapies All 82 Annamycin subjects (in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than traditional intensive therapy Annamycin is advancing towards pivotal AML stu...
Moleculin Biotech股票討論區
Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data
NEWS
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
2 MINUTES AGO, 9:05 AM EDT
VIA PR NEWSWIRE
Acute Myeloid Leukemia (AML) remains one of the most challenging blood cancers to treat, with survival rates that have seen only modest improvements over the past decades. However, a beacon of hope shines from recent developments in clinical trials conducted by Moleculin Biotech, Inc., showcasing significant progress in the battle against this devastat...
AnnAraC has potential to fill significant unmet need and expected to increase 2nd line AML CRs more than double over existing 2nd line therapies
All 82 Annamycin subjects (in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than traditional intensive therapy
Annamycin is advancing towards pivotal AML stu...
暫無評論